Secondly, mTOR inhibitors could be used in combination with standard treatment in patients with treatment-naïve advanced cholangiocarcinoma to investigate the possibly better response, progression-free survival and overall survival than conventional standard treatment. This evidence concerns the gene MTOR and cholangiocarcinoma.